The Journal of Experimental Medicine
R&D Systems
  Home | Help | Feedback | Subscriptions | Archive | Search | Latest Articles

Published online April 28, 2008
doi:10.1084/jem.2055iti4
The Journal of Experimental Medicine
The Rockefeller University Press, 0022-1007 $30.00
This Article
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
In This Issue

Dangers of restocking T cells

Autoimmune colitis (top) caused by homeostatically proliferating CD8+ T cells is resolved in mice injected with anti–IL-6 antibody (bottom).

Refilling an empty niche with proliferating CD8+ T cells can cause autoimmune disease, say Tajima et al.

Infusion of naive T cells into an environment where there are few native T cells—such as in patients undergoing cancer therapy—spurs two kinds of proliferation. T cells activated by non-self-peptide/MHC complexes proliferate rapidly, whereas those activated by self-peptide/MHC in the presence of cytokines such as IL-7 and IL-15 proliferate slowly. CD4 T cells that proliferate by these methods have previously been shown to drive the inflammation seen in several autoimmune diseases.

Tajima et al. now find a new variation in homeostatic proliferation of CD8+ T cells that also induces autoimmunity. In gut lymph nodes of T cell–deficient mice, injected CD8+ T cells proliferated rapidly in response to IL-6. This inflammatory cytokine was found at high levels in these lymph nodes, perhaps due to their proximity to the bacterium-laden gut.

The mice developed a thicker gut epithelium and lost weight—signs of an autoimmune disease called colitis. T cell–injected mice treated with an IL-6–blocking antibody or with bacterium-depleting drugs, however, remained healthy.

The proliferating T cells secreted several inflammatory cytokines, including IL-17. The IL-17 alone seemed to be responsible for the colitis, as mice injected with T cells that were unable to produce IL-17 remained healthy. If these IL-17–producing CD8+ T cells are found in patients suffering from diseases such as colitis, the anti–IL-6 antibody might be a good therapeutic option.

Hema Bashyam

hbashyam{at}rockefeller.edu



Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search